|
[1]
|
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors
Future Oncology,
2022
DOI:10.2217/fon-2022-0481
|
|
|
|
|
[2]
|
MicroRNAs and Natural Compounds Mediated Regulation of TGF Signaling in Prostate Cancer
Frontiers in Pharmacology,
2021
DOI:10.3389/fphar.2020.613464
|
|
|
|
|
[3]
|
ROLE OF THE TRANSFORMING GROWTH FACTOR β1 IN THE GENESIS OF ARTERIAL HYPERTENSION AND ITS COMPLICATIONS
Journal of the Grodno State Medical University,
2021
DOI:10.25298/2221-8785-2021-19-1-16-22
|
|
|
|
|
[4]
|
A Phase I Study of OMN54 (Aneustat™) in Patients with Advanced Malignancies
Clinical Cancer Drugs,
2020
DOI:10.2174/1574893615999200601130946
|
|
|
|
|
[5]
|
Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS‐986260, mitigates class‐based cardiovascular toxicity in dogs but not rats
Journal of Applied Toxicology,
2020
DOI:10.1002/jat.3954
|
|
|
|
|
[6]
|
Eugenol and capsaicin exhibit anti-metastatic activity via modulating TGF-β signaling in gastric carcinoma
Food & Function,
2020
DOI:10.1039/D0FO00887G
|
|
|
|
|
[7]
|
Design and synthesis of novel tranilast analogs: Docking, antiproliferative evaluation and in-silico screening of TGFβR1 inhibitors
Bioorganic Chemistry,
2020
DOI:10.1016/j.bioorg.2020.104368
|
|
|
|
|
[8]
|
Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS‐986260, mitigates class‐based cardiovascular toxicity in dogs but not rats
Journal of Applied Toxicology,
2020
DOI:10.1002/jat.3954
|
|
|
|
|
[9]
|
β-Peltoboykinolic Acid from Astilbe rubra Attenuates TGF-β1-Induced Epithelial-to-Mesenchymal Transitions in Lung Alveolar Epithelial Cells
Molecules,
2019
DOI:10.3390/molecules24142573
|
|
|
|
|
[10]
|
Targeted Intracellular Drug Delivery by Receptor Mediated Endocytosis
AAPS Advances in the Pharmaceutical Sciences Series,
2019
DOI:10.1007/978-3-030-29168-6_7
|
|
|
|
|
[11]
|
Biemamides A–E, Inhibitors of the TGF-β Pathway That Block the Epithelial to Mesenchymal Transition
Organic Letters,
2018
DOI:10.1021/acs.orglett.8b01871
|
|
|
|
|
[12]
|
Biemamides A–E, Inhibitors of the TGF-β Pathway That Block the Epithelial to Mesenchymal Transition
Organic Letters,
2018
DOI:10.1021/acs.orglett.8b01871
|
|
|
|
|
[13]
|
A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF‐β Responsiveness by Inhibiting TGF‐β Type I Receptor Serine/Threonine Kinase Activity
Journal of Cellular Biochemistry,
2016
DOI:10.1002/jcb.25581
|
|
|
|
|
[14]
|
Effects of Two Common Promoter Polymorphisms of Transforming Growth Factor-β1 on Breast Cancer Risks in Ahvaz, West South of Iran
Iranian Journal of Cancer Prevention,
2016
DOI:10.17795/ijcp-5266
|
|
|
|
|
[15]
|
P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines
Cancer Letters,
2016
DOI:10.1016/j.canlet.2016.07.029
|
|
|
|
|
[16]
|
A Small Dibromotyrosine Derivative Purified FromPseudoceratinaSp. Suppresses TGF-β Responsiveness by Inhibiting TGF-β Type I Receptor Serine/Threonine Kinase Activity
Journal of Cellular Biochemistry,
2016
DOI:10.1002/jcb.25581
|
|
|
|